Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q4 2025 ▲▼ | Q1 2026 ▲▼ | Change ▲▼ | Q4 2025 ▲▼ | Q1 2026 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Arcellx, Inc. COMMON STOCK | 2,346,630 | 2,346,630 | 0 | $153.00M | $269.44M | 29.43% | +$116.44M |
| Veradermics, Incorporated(MANE) | 0 | 2,401,868 | +2,401,868 | $0 | $151.68M | 16.57% | +$151.68M |
| Zenas BioPharma, Inc.(ZBIO) | 5,037,854 | 5,037,854 | 0 | $182.92M | $98.49M | 10.76% | -$84.43M |
| CRISPR Therapeutics AG(CRSP) | 2,038,763 | 2,038,763 | 0 | $106.91M | $96.98M | 10.59% | -$9.93M |
| Design Therapeutics, Inc.(DSGN) | 6,526,476 | 6,526,476 | 0 | $61.22M | $69.44M | 7.59% | +$8.22M |
| ORIC Pharmaceuticals, Inc.(ORIC) | 4,514,929 | 4,514,929 | 0 | $37.75M | $58.48M | 6.39% | +$20.72M |
| Alumis Inc. | 1,959,896 | 1,959,896 | 0 | $19.13M | $43.18M | 4.72% | +$24.05M |
| Mineralys Therapeutics, Inc.(MLYS) | 1,563,966 | 1,563,966 | 0 | $56.76M | $42.37M | 4.63% | -$14.39M |
| ARS Pharmaceuticals, Inc.(SPRY) | 4,012,903 | 4,012,903 | 0 | $46.75M | $32.22M | 3.52% | -$14.53M |
| Oruka Therapeutics, Inc.(ORKA) | 430,330 | 430,330 | 0 | $13.04M | $21.11M | 2.31% | +$8.06M |
| Oculis Holding AG(OCS) | 641,022 | 641,022 | 0 | $12.80M | $17.04M | 1.86% | +$4.24M |
| Nkarta, Inc.(NKTX) | 3,333,333 | 3,333,333 | 0 | $6.17M | $7.03M | 0.77% | +$866.7K |
| enGene Holdings Inc. COM | 747,750 | 747,750 | 0 | $6.75M | $5.09M | 0.56% | -$1.66M |
| Ultragenyx Pharmaceutical Inc.(RARE) | 137,753 | 137,753 | 0 | $3.17M | $2.89M | 0.32% | -$282.4K |